Circumventing multidrug resistance in cancer by β-galactoside binding protein, an antiproliferative cytokine

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1631-1634

  Ravatn, Roald ^a   Wells, Valerie ^b   Nelson, Leigh ^a   Vettori, David ^a   Mallucci, Livio ^b   Chin, Khew Voon ^a  

^a RUTGERS UNIVERSITY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CYTOKINE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GALAPTIN; RECOMBINANT BETA GALACTOSIDE BINDING PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; GENE MUTATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GALECTINS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; RECOMBINANT PROTEINS; S PHASE; TUMOR CELLS, CULTURED;

EID: 16444368030     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1970     Document Type: Article

References (20)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
2. Kudoh K, Ramanna M, Ravatn R, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000;60:4161-6.
3. Sharma R, Awasthi YC, Yang Y, Sharma A, Singhal SS, Awasthi S. Energy dependent transport of xenobiotics and its relevance to multidrug resistance. Curr Cancer Drug Targets 2003;3:89-107.
4. Doherty MM, Michael M. Tumoral drug metabolism: perspectives and therapeutic implications. Curr Drug Metab 2003;4:131-49.
5. Liem AA, Chamberlain MP, Wolf CR, Thompson AM. The role of signal transduction in cancer treatment and drug resistance. Eur J Surg Oncol 2002;28:679-84.
6. Schmitt CA, Lowe SW. Apoptosis and chemoresistance in transgenic cancer models. J Mol Med 2002;80:137-46.
7. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21.
8. Wells V, Mallucci L. Identification of an autocrine negative growth factor: mouse β-galactoside-binding protein is a cytostatic factor and cell growth regulator. Cell 1991;64:91-7.
9. Mallucci L, Wells V, Danikas A, Davies D. Turning cell cycle controller genes into cancer drugs. A role for an antiproliferative cytokine (βGBP). Biochem Pharmacol 2003;66:1563-9.
10. Blaser C, Kaufmann M, Muller C, et al. β-Galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 1998;28:2311-9.
11. Wells V, Davies D, Mallucci L. Cell cycle arrest and induction of apoptosis by β-galactoside binding protein (βGBP) in human mammary cancer cell. A potential new approach to cancer control. Eur J Cancer 1999;35:978-83.
12. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 1985;11:117-26.
13. Taylor CW, Dalton WS, Parrish PR. et al. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 1991;63:923-9.
14. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987;19:149-54.
15. Saleem A, Ibrahim N, Patel M, et al. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res 1997;57:5100-6.
16. Horio M, Chin KV, Currier SJ, et al. Transepithelial transport of drugs by the muitidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 1989;264:14880-4.
17. Heeg K, Reimann J, Kabelitz D, Hardt C, Wagner H. A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J Immunol Methods 1985;77:237-46.
18. Hirabayashi J, Ayaki H, Soma G, Kasai K. Production and purification of a recombinant human 14 kDa β-galactoside-binding lectin. FEBS Lett 1989;250:161-5.
19. Novelli F, Allione A, Wells V, Forni G, Mallucci L. Negative cell cycle control of human T cells by β-galactoside binding protein (βGBP): induction of programmed cell death in leukaemic cells. J Cell Physiol 1999;178:102-8.
20. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.